A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection
Emory University · University of the Witwatersrand · +4 more institutions
Abstract
Acute respiratory tract infections caused by Streptococcus pneumoniae are a leading cause of morbidity and mortality in young children. We evaluated the efficacy of a 9-valent pneumococcal conjugate vaccine in a randomized, double-blind study in Soweto, South Africa.
At 6, 10, and 14 weeks of age, 19,922 children received the 9-valent pneumococcal polysaccharide vaccine conjugated to a noncatalytic cross-reacting mutant of diphtheria toxin (CRM197), and 19,914 received placebo. All children received Haemophilus influenzae type b conjugate vaccine. Efficacy and safety were analyzed according to the intention-to-treat principle.
Citation impact
- FWCI
- 38.16
- Percentile
- 100%
- References
- 25
Authors
6- KPKeith P. KlugmanCorresponding
Emory University, University of the Witwatersrand, Respiratory and Meningeal Pathogens Research Unit
- SAShabir A. Madhi
University of the Witwatersrand, Respiratory and Meningeal Pathogens Research Unit
- RHRobin Huebner
University of the Witwatersrand, Respiratory and Meningeal Pathogens Research Unit
- RKRobert Kohberger
Pearl River Community College, Pearl River Hydraulic Research Institute
- NMNontombi Mbelle
University of the Witwatersrand, Respiratory and Meningeal Pathogens Research Unit
Topics & keywords
- Medicine
- Pneumococcal conjugate vaccine
- Confidence interval
- Streptococcus pneumoniae
- Pneumococcal vaccine
- Incidence (geometry)
- Internal medicine
- Pediatrics
- Good health and well-being